Phase 1 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years old or older at the time of giving consent to participate
- People whose cancer can be measured using standard imaging methods (a system called RECIST v1.1)
- People who are relatively well and able to carry out daily activities, based on a standard health performance scale (ECOG score of 0 or 1)
- People who are expected to live for at least 3 months, in the opinion of the study doctor
- People for whom enough time has passed since finishing previous cancer treatments before starting this trial (confirm with trial site for specific timeframes)
- People who agree to use an effective method of contraception during the trial
- For one part of the trial (Part 1): People whose cancer is a solid tumour that has spread locally or to other parts of the body, confirmed by tissue or cell testing, and is not located in the brain or central nervous system
- For another part of the trial (Part 2): People whose cancer is stomach (gastric) adenocarcinoma, cancer at the junction of the stomach and oesophagus (GEJ), oesophageal adenocarcinoma, or a type of lung cancer called non-small cell lung cancer (NSCLC), confirmed by tissue or cell testing
- For Part 2: People whose doctor considers them suitable to receive a chemotherapy medicine called docetaxel
Who may not be able to join:
- People who have a serious or uncontrolled illness alongside their cancer
- People who have active cancer spread to the brain or central nervous system
- People who have had a severe (Grade 3 or higher) allergic reaction to any antibody-based medicine in the past
- People who have a history of autoimmune disease (conditions where the immune system attacks the body)
- People who have a history of HIV, hepatitis B (HBV), or hepatitis C (HCV), identified during screening
- People who have a history of a primary immune deficiency condition (a condition where the immune system does not work properly from birth or early life)
- For Part 2 only: People who have previously been treated with docetaxel
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +81-3-5205-7200
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Subjects Experiencing Dose-limiting Toxicity; Number of Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.